Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Apr 26, 2018 11:06am
76 Views
Post# 27944127

RE:RE:RE:RE:CEO Letter is a great .40 to .50 channel trading remedy

RE:RE:RE:RE:CEO Letter is a great .40 to .50 channel trading remedyYou're post title is mis-leading. This letter is not the the remedy to get us out of the 40-50 channel. Real news is and this is largely an overview of what we already knew.

We largely already knew the main bulk of this letter about the commercialization strategy. In fact in some ways this letter further cements the idea that there will be no early surprises, the major market deal will be a long, drawn out affair. They maybe approaching global companies now but the bulk of that process might not begin until AFTER  the end of the next trial. In my mind that actually stretches the timeline.The only real piece of new hard news is the Benco deal. The potential long term strategy for Citagenix is intriguing. The Nasdaq stuff is fairy dust atm, show me a tech/biotech that isnt "exploring" a listing on Nasdaq, those are just cheap words on paper atm.

Its certainly great to see the proposition laid out like this but I dont see how it adds value or moves the SP in a meaningful way.

I understand I get ignored, I want to talk about risk that pisses people off, many people like you just want to dream.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities